Kiniksa Pharmaceuticals, Ltd. (KNSA)

NASDAQ: KNSA · IEX Real-Time Price · USD
20.38
-0.51 (-2.44%)
Feb 28, 2024, 2:56 PM EST - Market open
-2.44%
Market Cap 1.42B
Revenue (ttm) 248.75M
Net Income (ttm) -6.69M
Shares Out 70.34M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 371,568
Open 21.92
Previous Close 20.89
Day's Range 19.20 - 21.98
52-Week Range 10.29 - 21.98
Beta 0.24
Analysts Strong Buy
Price Target 25.67 (+25.96%)
Earnings Date Feb 28, 2024

About KNSA

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arter... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 24, 2018
Employees 220
Stock Exchange NASDAQ
Ticker Symbol KNSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price forecast is $25.67, which is an increase of 25.96% from the latest price.

Price Target
$25.67
(25.96% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively –

7 hours ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

HAMILTON, Bermuda, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, February 28, 2024 a...

6 days ago - GlobeNewsWire

Kiniksa Pharmaceuticals Provides Corporate Update

– ARCALYST ® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) –

7 weeks ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference

HAMILTON, Bermuda, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, J...

2 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth –

4 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023

HAMILTON, Bermuda, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 31, 2023 at 8...

4 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q2 2023 net product revenue of $54.5 million – – ARCALYST 2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the m...

7 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023

HAMILTON, Bermuda, July 17, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30...

8 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

HAMILTON, Bermuda, June 06, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Goldman Sachs 44th Annual G...

9 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q1 2023 net product revenue of $42.7 million – – ARCALYST full-year 2023 net product revenue guidance increased to $200 - $215 million, representing ~69% year-over-year growt...

10 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023

HAMILTON, Bermuda, May 01, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 2, 2023, at 8:30 a...

10 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively –

1 year ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023

HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at...

1 year ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference

HAMILTON, Bermuda, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, J...

1 year ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference

HAMILTON, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Bank of America Securities ...

1 year ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference

HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual Hea...

1 year ago - GlobeNewsWire

Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

– ARCALYST ® (rilonacept) Q3 2022 net revenue of $33.4 million – – RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard...

1 year ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022

HAMILTON, Bermuda, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, November 1, 2022, at ...

1 year ago - GlobeNewsWire

Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab

HAMILTON, Bermuda, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological ...

1 year ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference

HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that its management will participate in a fireside chat at the 2022 Wedbush PacGrow He...

1 year ago - GlobeNewsWire

Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

– ARCALYST ® (rilonacept) net revenue of $27.0 million in Q2 2022 –

1 year ago - GlobeNewsWire

Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab

– Kiniksa to receive $100 million in upfront and near-term payments –

1 year ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

HAMILTON, Bermuda, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, August 3, 2022, at ...

1 year ago - GlobeNewsWire

Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

– ARCALYST ® (rilonacept) net revenue of $22.2 million in Q1 2022 –

1 year ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022

HAMILTON, Bermuda, May 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 3, 2022, at 8:30 a...

1 year ago - GlobeNewsWire